Prognostic significance of in situ and plasma levels of transforming growth factor β1, -2 and -3 in cutaneous melanoma

Tang,Ming‑Rui; Wang,Yu‑Xin; Guo,Shu; Han,Si‑Yuan; Li,He‑Huan; Jin,Shi‑Feng

doi:10.3892/mmr.2015.3250

Prognostic significance of in situ and plasma levels of transforming growth factor β1, -2 and -3 in cutaneous melanoma

Authors:
- Ming‑Rui Tang
- Yu‑Xin Wang
- Shu Guo
- Si‑Yuan Han
- He‑Huan Li
- Shi‑Feng Jin
View Affiliations

Affiliations: Department of Plastic Surgery, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China
Published online on: January 26, 2015 https://doi.org/10.3892/mmr.2015.3250
Pages: 4508-4512

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Melanoma is an aggressive type of cutaneous malignancy. Transforming growth factor (TGF)‑β has been demonstrated to be an important mediator of tumor progression. However, to the best of our knowledge, the systemic roles of plasma TGF‑β and TGF‑β in situ have not been investigated in Han Chinese melanoma patients. The results of the present study demonstrated that the in situ and plasma levels of TGF‑β1, TGF‑β2 and TGF‑β3 protein and messenger RNA were significantly elevated in tumor tissues compared with those of normal tissues. The survival rates of the patients which were triple‑positive (TGF‑β1+, TGF‑β2+ and TGF‑β3+) were found to be markedly decreased compared to those which were single‑ (TGF‑β1+, TGF‑β2+ or TGF‑β3+) or double‑positive (TGF‑β1+, TGF‑β2+; TGF‑β2+, TGF‑β3+; or TGF‑β1+, TGF‑β3+). These results may therefore contribute to the use of TGF‑β as a prognostic biomarker, and to the development of novel therapies for melanoma treatment.

View Figures

View References

1	Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Diffey BL: The future incidence of cutaneous melanoma within the UK. Br J Dermatol. 151:868–872. 2004. View Article : Google Scholar : PubMed/NCBI
3	Sousa JF, Torrieri R, Silva RR, et al: Novel primate specific genes, RMEL 1, 2 and 3, with highly restricted expression in melanoma, assessed by new data mining tool. PLoS One. 5:e135102010. View Article : Google Scholar
4	Massague J: How cells read TGF-beta signals. Nat Rev Mol Cell Biol. 1:169–178. 2000. View Article : Google Scholar
5	Derynck R and Zhang YE: Smad-dependent and Smad independent pathways in TGF-beta family signalling. Nature. 425:577–584. 2003. View Article : Google Scholar : PubMed/NCBI
6	Wu MY and Hill CS: Tgf-beta superfamily signaling in embryonic development and homeostasis. Dev Cell. 16:329–343. 2009. View Article : Google Scholar : PubMed/NCBI
7	Roberts AB and Wakefeld LM: The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci USA. 100:8621–8623. 2003. View Article : Google Scholar : PubMed/NCBI
8	Busse A and Keilholz U: Role of TGF-β in melanoma. Curr Pharm Biotechnol. 12:2165–2175. 2011. View Article : Google Scholar : PubMed/NCBI
9	Lasfar A and Cohen-Solal KA: Resistance to transforming growth factor β-mediated tumor suppression in melanoma: are multiple mechanisms in place? Carcinogenesis. 31:1710–1717. 2010. View Article : Google Scholar : PubMed/NCBI
10	Malaponte G, Zacchia A, Bevelacqua Y, et al: Co-regulated expression of matrix metalloproteinase-2 and transforming growth factor-beta in melanoma development and progression. Oncol Rep. 24:81–87. 2010. View Article : Google Scholar : PubMed/NCBI
11	Goel MK, Khanna P and Kishore J: Understanding survival analysis: Kaplan-Meier estimate. Int J Ayurveda Res. 1:274–278. 2010. View Article : Google Scholar
12	Massagué J: TGFbeta in Cancer. Cell. 134:215–230. 2008. View Article : Google Scholar : PubMed/NCBI
13	Leivonen SK and Kähäri VM: Transforming growth factor-beta signaling in cancer invasion and metastasis. Int J Cancer. 121:2119–2124. 2007. View Article : Google Scholar : PubMed/NCBI
14	Albino AP, Davis BM and Nanus DM: Induction of growth factor RNA expression in human malignant melanoma: markers of transformation. Cancer Res. 51:4815–4820. 1991.PubMed/NCBI
15	Bursch W, Oberhammer F and Schulte-Hermann R: Cell death and its protective role in disease. Trends Pharmacol Sci. 13:245–251. 1992. View Article : Google Scholar : PubMed/NCBI
16	Schmid P, Itin P and Rufli T: In situ analysis of transforming growth factor-betas (TGF-beta 1, TGF-beta 2, TGF-beta 3), and TGF-beta type II receptor expression in malignant melanoma. Carcinogenesis. 16:1499–1503. 1995. View Article : Google Scholar : PubMed/NCBI
17	Van Belle P, Rodeck U, Nuamah I, Halpern AC and Elder DE: Melanoma-associated expression of transforming growth factor-beta isoforms. Am J Pathol. 148:1887–1894. 1996.PubMed/NCBI
18	Rodeck U, Bossler A, Graeven U, et al: Transforming growth factor b production and responsiveness in normal human melanocytes and melanoma cells. Cancer Res. 54:575–581. 1994.PubMed/NCBI
19	Krasagakis K, Tholke D, Farthmann B, Eberle J, Mansmann U and Orfanos CE: Elevated plasma levels of transforming growth factor (TGF)-b1 and TGF-b2 in patients with disseminated malignant melanoma. Br J Cancer. 77:1492–1494. 1998. View Article : Google Scholar : PubMed/NCBI